Shang Hai Zheng Quan Bao·2026-02-05 18:44Core Viewpoint - The actual controller of Baolingbao Biotech Co., Ltd., Mr. Dai Sichong, has expanded the shareholding plan to include a new entity, CEDARWALK BIOTECH HONG KONG LIMITED, to facilitate the acquisition of shares in the company [1][2]. Summary by Sections Shareholding Plan Overview - The original plan was to increase shareholding by 18,488,369 shares (5% of total shares) to a maximum of 36,976,738 shares (10% of total shares) starting from October 8, 2024, for a period of six months [1]. - The plan has been extended by 12 months, now set to conclude on April 7, 2026, while other details remain unchanged [2]. Addition of New Entity - CEDARWALK BIOTECH HONG KONG LIMITED has been added as a new entity to the shareholding plan, which is controlled by Mr. Dai Sichong [2][3]. - This entity will operate through a specific investment account managed by Guotou Securities Asset Management (Hong Kong) [2]. Shareholding Changes - As of February 4, 2026, the cumulative shares acquired by Shenzhen Songjing Investment Partnership and CEDARWALK BIOTECH HONG KONG LIMITED amount to 6,375,700 shares, representing 1.67531% of the total shares [3]. - The total shares acquired from November 2025 to February 2026 reached 5,076,300 shares, increasing the combined holding to 13.99607% [4]. Compliance and Commitments - The shareholding plan complies with relevant laws and regulations, ensuring that it does not affect the company's listing status or control [6]. - CEDARWALK BIOTECH HONG KONG LIMITED has committed to not reducing its holdings for six months post-acquisition [6].